메뉴 건너뛰기




Volumn 28, Issue 1, 2013, Pages 80-86

Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation

(16)  Lee, Ho Sup a   Kim, Yang Soo a   Kim, Kihyun b   Kim, Jin Seok c   Kim, Hyo Jung d   Min, Chang Ki e   Suh, Cheolwon f   Eom, Hyeon Seok g   Yoon, Sung Soo h   Lee, Jae Hoon i   Kim, Min Kyong j   Kim, Sung Hyun k   Bae, Sung Hwa l   Mun, Yeung Chul m   Jo, Deog Yeon n   Chung, Joo Seop o  


Author keywords

Bortezomib; Early Response; Multiple Myeloma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; PYRAZINE DERIVATIVE;

EID: 84874778308     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.1.80     Document Type: Article
Times cited : (3)

References (25)
  • 1
    • 32644438680 scopus 로고    scopus 로고
    • Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
    • Facon T, Mary JY, Pegourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292-8.
    • (2006) Blood , vol.107 , pp. 1292-1298
    • Facon, T.1    Mary, J.Y.2    Pegourie, B.3    Attal, M.4    Renaud, M.5    Sadoun, A.6    Voillat, L.7    Dorvaux, V.8    Hulin, C.9    Lepeu, G.10
  • 3
    • 0025064260 scopus 로고
    • VAD-based regimens as primary treatment for multiple myeloma
    • Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-9.
    • (1990) Am J Hematol , vol.33 , pp. 86-89
    • Alexanian, R.1    Barlogie, B.2    Tucker, S.3
  • 6
    • 0012689130 scopus 로고    scopus 로고
    • Impact on survival of highdose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study
    • Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, et al. Impact on survival of highdose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7-11.
    • (2000) Blood , vol.95 , pp. 7-11
    • Lenhoff, S.1    Hjorth, M.2    Holmberg, E.3    Turesson, I.4    Westin, J.5    Nielsen, J.L.6    Wisloff, F.7    Brinch, L.8    Carlson, K.9    Carlsson, M.10
  • 9
    • 77950607507 scopus 로고    scopus 로고
    • Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
    • Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348-53.
    • (2010) Blood , vol.115 , pp. 2348-2353
    • Gertz, M.A.1    Kumar, S.2    Lacy, M.Q.3    Dispenzieri, A.4    Dingli, D.5    Hayman, S.R.6    Buadi, F.K.7    Hogan, W.J.8
  • 10
    • 61749103773 scopus 로고    scopus 로고
    • Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation
    • Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM,Yoon SS, Lee JH. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant 2009; 15: 463-70.
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 463-470
    • Kim, J.S.1    Kim, K.2    Cheong, J.W.3    Min, Y.H.4    Suh, C.5    Kim, H.6    Jo, D.Y.7    Ryoo, H.M.8    Yoon, S.S.9    Lee, J.H.10
  • 11
    • 33646339149 scopus 로고    scopus 로고
    • Complete response in multiple myeloma: clinical trial E9486, an Eastern CooperativeOncology Group study not involving stem cell transplantation
    • Kyle RA, Leong T, Li S, Oken MM, Kay NE, VanNess B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern CooperativeOncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958-66.
    • (2006) Cancer , vol.106 , pp. 1958-1966
    • Kyle, R.A.1    Leong, T.2    Li, S.3    Oken, M.M.4    Kay, N.E.5    VanNess, B.6    Greipp, P.R.7
  • 13
    • 54049135250 scopus 로고    scopus 로고
    • Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    • Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112: 3107-14.
    • (2008) Blood , vol.112 , pp. 3107-3114
    • Palumbo, A.1    Bringhen, S.2    Liberati, A.M.3    Caravita, T.4    Falcone, A.5    Callea, V.6    Montanaro, M.7    Ria, R.8    Capaldi, A.9    Zambello, R.10
  • 14
    • 68949137225 scopus 로고    scopus 로고
    • Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    • Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-70.
    • (2009) J Clin Oncol , vol.27 , pp. 3664-3670
    • Hulin, C.1    Facon, T.2    Rodon, P.3    Pegourie, B.4    Benboubker, L.5    Doyen, C.6    Dib, M.7    Guillerm, G.8    Salles, B.9    Eschard, J.P.10
  • 15
    • 8344251663 scopus 로고    scopus 로고
    • Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma
    • Ross DM, To LB, Horvath N. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Intern Med J 2004; 34: 576-8.
    • (2004) Intern Med J , vol.34 , pp. 576-578
    • Ross, D.M.1    To, L.B.2    Horvath, N.3
  • 16
    • 77950660221 scopus 로고    scopus 로고
    • Early response predicts myeloma outcome
    • Palumbo A. Early response predicts myeloma outcome. Blood 2010; 115: 2332-3.
    • (2010) Blood , vol.115 , pp. 2332-2333
    • Palumbo, A.1
  • 19
    • 34848833957 scopus 로고    scopus 로고
    • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    • Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-18.
    • (2007) Lancet , vol.370 , pp. 1209-1218
    • Facon, T.1    Mary, J.Y.2    Hulin, C.3    Benboubker, L.4    Attal, M.5    Pegourie, B.6    Renaud, M.7    Harousseau, J.L.8    Guillerm, G.9    Chaleteix, C.10
  • 21
    • 80051548597 scopus 로고    scopus 로고
    • Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
    • Shah J, Blade J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 2011; 117: 3758-62.
    • (2011) Cancer , vol.117 , pp. 3758-3762
    • Shah, J.1    Blade, J.2    Sonneveld, P.3    Harousseau, J.L.4    Lantz, K.5    Londhe, A.6    Lowery, C.7    Orlowski, R.Z.8
  • 22
    • 70350094381 scopus 로고    scopus 로고
    • International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
    • Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716-30.
    • (2009) Leukemia , vol.23 , pp. 1716-1730
    • Palumbo, A.1    Sezer, O.2    Kyle, R.3    Miguel, J.S.4    Orlowski, R.Z.5    Moreau, P.6    Niesvizky, R.7    Morgan, G.8    Comenzo, R.9    Sonneveld, P.10
  • 23
    • 78149443734 scopus 로고    scopus 로고
    • Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
    • Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010; 116: 3743-50.
    • (2010) Blood , vol.116 , pp. 3743-3750
    • Harousseau, J.L.1    Palumbo, A.2    Richardson, P.G.3    Schlag, R.4    Dimopoulos, M.A.5    Shpilberg, O.6    Kropff, M.7    Kentos, A.8    Cavo, M.9    Golenkov, A.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.